Outlining 2016’s big opportunities
Pharmaceutical companies are facing an increasingly crowded marketplace and escalating compliance costs. As pressure mounts to make efficiencies, supply chains are emerging as the competitive battleground of the future. The right improvements can reduce costs, drive quality and minimise risks.
Smurfit Kappa is providing an exclusive opportunity to leverage insights, gained from working with over 1,200 pharmaceutical supply chains, in an ongoing initiative to support supply chain professionals worldwide.
In this free webinar, we will:
> Outline the key opportunities to unlock supply chain value in 2016.
> Look at what action industry leaders are taking to capitalise on these opportunities.
> Reveal 3 practical measures you can take to unlock the latent value in your supply chain.
Introducing the speakers…
Director in Deloitte’s UK Strategy & Operations Consulting Practice
John specialises in Life Sciences Supply Chain and has 18 years of experience in supply chain transformation. He has extensive international work experience and has led engagements in Europe and North America. In this webinar, he’ll outline the key supply chain opportunities for pharmaceuticals.
Lean and Innovation Coach & Author of The Financial Times Guide to Lean
Andy is a certified Master Lean Six Sigma Black Belt, who’s spent 16 years advising a diverse range of companies on their supply chains. He has authored several books in Lean Innovation. Andy is joining us to discuss how leaders from other industries are streamlining their operations.
UK Market Director
Jason has over 25 years’ experience working with global manufacturing companies across multiple sectors. As facilitator of this webinar, he will be providing practical advice to pinpoint the areas that will deliver the biggest impact on optimising pharmaceutical supply chains.
Smurfit Kappa is one of the leading providers of paper-based packaging solutions in the world, with around 45,000 employees in approximately 350 production sites across 34 countries and with revenue of €8.1 billion.